Fabry disease in unselected patients with TIA or stroke: Population-based study

European Journal of Neurology

Volumn 19, Issue 11, 2012, Pages 1427-1432

  Marquardt, L ^a,b   Baker, R ^c   Segal, H ^a   Burgess, A I ^a   Poole, D ^a   Hughes, D A ^c   Rothwell, P M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Cerebral infarction; Epidemiology; Genetic and inherited disorders; Stroke; TIA

Indexed keywords

ALPHA GALACTOSIDASE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FABRY DISEASE; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-GALACTOSIDASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA MUTATIONAL ANALYSIS; FABRY DISEASE; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; STROKE; YOUNG ADULT;

EID: 84867725412     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03739.x     Document Type: Article

References (21)

1. Desnick RJ, Ioannou YA, Eng CM. Alpha-galactosidase a deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease, 8th edn. New York, NY: McGraw-Hill, 2001: 3733-3774.
2. Fabry H. An historical overview of Fabry disease. J Inherit Metab Dis 2001; 24: 3-7.
3. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281: 249-254.
4. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34: 236-242.
5. Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 2008; 93: 112-128.
6. Zarate YA, Hopkin RJ. Fabry's disease. Lancet 2008; 372: 1427-1435.
7. Schiffmann R. Fabry disease. Pharmacol Ther 2009; 122: 65-77.
8. Moore DF, Scott LT, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001; 104: 1506-1512.
9. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33: 525-531.
10. Mehta A, Ginsberg L, FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl 2005; 94: 24-27.
11. Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005; 366: 1794-1796.
12. Brouns R, Sheorajpanday R, Braxel E, et al. Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Clin Neurol Neurosurg 2007; 109: 479-484.
13. Wozniak MA, Kittner SJ, Tuhrim S, et al. Frequency of unrecognized Fabry disease among young European-American and African-American men with first ischemic stroke. Stroke 2010; 41: 78-81.
14. Baptista MV, Ferreira S, Pinho-E-Melo T, et al.PORTuguese Young STROKE Investigators. Mutations of the GLA gene in young patients with stroke: the PORTYSTROKE study-screening genetic conditions in Portuguese young stroke patients. Stroke 2010; 41: 431-436.
15. Rothwell PM, Coull AJ, Giles M; for the Oxford Vascular Study. Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). Lancet 2004; 363: 1925-1933.
16. Rothwell PM, Coull AJ, Silver LE. Population-based study of event-rate, incidence, case fatality and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366: 1773-1783.
17. Froissart R, Guffon N, Vanier MT, Desnick RJ, Maire I. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab 2003; 80: 307-314.
18. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 2003; 22: 486-492.
19. Barr C, Clarke JT, Ntwari A, Drouin R, Auray-Blais C. Fabry disease urinary globotriaosylceramide/creatinine biomarker evaluation by liquid chromatography-tandem mass spectrometry in healthy infants from birth to 6 months. Mol Genet Metab 2009; 97: 278-283.
20. Brouns R, Thijs V, Eyskens F, et al.BeFaS Investigators. Belgian Fabry study: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke 2010; 41: 863-868.
21. Nakamura K, Sekijima Y, Nakamura K, et al. Cerebral hemorrhage in Fabry's disease. J Hum Genet 2010; 55: 259-261.